A Single Arm, Open, Exploratory Clinical Trial to Evaluate Efficacy and Safety for Combination Treatment of Replication Competent Adenovirus Double Suicide Gene Therapy(Theragene®,Ad5-yCD/mutTKSR39rep-ADP) and Radiation Therapy in Patients
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Ad5 yCD/mutTK(SR39)rep ADP (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 15 Mar 2021 Status changed from not yet recruiting to recruiting.
- 10 Feb 2021 New trial record